C4 Therapeutics Inc (NAS:CCCC)

$ 4.06 -0.24 (-5.58%) Market Cap: 286.59 Mil Enterprise Value: 114.99 Mil PE Ratio: 0 PB Ratio: 1.25 GF Score: 60/100

C4 Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
C4 Therapeutics Inc To Discuss CFT7455 Phase 1 Update Call Transcript
Dec 12, 2023
C4 Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 26, 2023
C4 Therapeutics Inc at Wells Fargo Targeted Protein Degradation Summit (Virtual) - Panel Discussion Transcript
Feb 21, 2023
C4 Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
C4 Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022
C4 Therapeutics Inc at Bank of America Precision Oncology Conference Transcript
Oct 03, 2022
C4 Therapeutics Inc To Discuss CFT7455 Cohort Clinical Data Call Transcript
Apr 08, 2022
C4 Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
C4 Therapeutics Inc CFT8919 Pre-Clinical Data Call Transcript
Jun 07, 2021
C4 Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 01, 2021
C4 Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript
May 26, 2021
C4 Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021

C4 Therapeutics Inc To Discuss CFT7455 Phase 1 Update Call Transcript

Dec 12, 2023 / 09:30PM GMT

Release Date Price: $2.34 (+98.31%)

Transcript

Operator

Hello, and welcome to the CFT7455 Phase 1 update investor call. (Operator Instructions)

Please note this event is being recorded. I would now like to hand the call to Courtney Solberg. Please go ahead.

Courtney Solberg C4 Therapeutics;Andrew Hirsch C4

Inc. - Senior Manager of IR

Good afternoon, everyone, and thank you for joining our call to discuss Phase 1 dose escalation clinical data of CFT7455 for the potential treatment of relapse refractory multiple myeloma. We're making forward-looking statements today and Slide 2 contains our legal disclaimer on this matter.

Those presenting on today's call are Andrew Hirsch, our President and CEO; Steve Fisher, our Chief Scientific Officer; and Len Reyno, our Chief Medical Officer. We'll begin the opening remarks and then walk you through our preclinical and dose escalation clinical data of CFT7455 in relapse refractory multiple myeloma.

We will end today's call with a Q&A session. I will now turn the call over to Andrew Hirsch for some introductory remarks.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.